Concepts (245)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Metformin | 9 | 2025 | 125 | 3.560 |
Why?
|
| Ovarian Neoplasms | 19 | 2025 | 800 | 3.430 |
Why?
|
| Culturally Competent Care | 2 | 2017 | 13 | 1.080 |
Why?
|
| Hypoglycemic Agents | 5 | 2019 | 376 | 0.930 |
Why?
|
| Sexual and Gender Minorities | 2 | 2017 | 250 | 0.820 |
Why?
|
| Gynecology | 2 | 2023 | 130 | 0.650 |
Why?
|
| Obstetrics | 2 | 2023 | 123 | 0.650 |
Why?
|
| Calcium, Dietary | 4 | 2024 | 68 | 0.590 |
Why?
|
| BRCA1 Protein | 2 | 2018 | 216 | 0.590 |
Why?
|
| Glycolysis | 2 | 2017 | 191 | 0.580 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2019 | 81 | 0.570 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2016 | 68 | 0.560 |
Why?
|
| Food, Fortified | 3 | 2024 | 18 | 0.550 |
Why?
|
| Maternal Health Services | 1 | 2017 | 16 | 0.540 |
Why?
|
| Marriage | 1 | 2017 | 25 | 0.540 |
Why?
|
| Homosexuality, Female | 1 | 2017 | 17 | 0.540 |
Why?
|
| Fertilization in Vitro | 1 | 2017 | 59 | 0.540 |
Why?
|
| Spouses | 1 | 2017 | 32 | 0.530 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2017 | 78 | 0.490 |
Why?
|
| Carcinosarcoma | 1 | 2016 | 29 | 0.470 |
Why?
|
| Epithelial Cells | 2 | 2017 | 705 | 0.470 |
Why?
|
| Tumor Microenvironment | 3 | 2019 | 556 | 0.470 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2016 | 61 | 0.460 |
Why?
|
| Parents | 1 | 2017 | 307 | 0.430 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2025 | 2605 | 0.430 |
Why?
|
| Female | 31 | 2025 | 49872 | 0.430 |
Why?
|
| Hyperglycemia | 1 | 2015 | 181 | 0.420 |
Why?
|
| Hyperlipidemias | 1 | 2014 | 91 | 0.420 |
Why?
|
| Cell Line, Tumor | 10 | 2020 | 2777 | 0.400 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2015 | 1346 | 0.400 |
Why?
|
| Genital Neoplasms, Female | 1 | 2014 | 114 | 0.390 |
Why?
|
| Flour | 2 | 2024 | 4 | 0.390 |
Why?
|
| Endometrial Neoplasms | 1 | 2016 | 228 | 0.390 |
Why?
|
| Paclitaxel | 1 | 2014 | 488 | 0.380 |
Why?
|
| Delivery of Health Care | 1 | 2017 | 468 | 0.380 |
Why?
|
| Antineoplastic Agents | 5 | 2020 | 2385 | 0.380 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2013 | 463 | 0.380 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2011 | 34 | 0.350 |
Why?
|
| Estradiol | 1 | 2011 | 255 | 0.330 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 395 | 0.330 |
Why?
|
| Adipocytes | 3 | 2020 | 170 | 0.310 |
Why?
|
| Contraceptives, Oral, Synthetic | 1 | 2009 | 6 | 0.310 |
Why?
|
| Humans | 34 | 2025 | 95802 | 0.310 |
Why?
|
| Ethinyl Estradiol | 1 | 2009 | 16 | 0.310 |
Why?
|
| Indoles | 1 | 2011 | 317 | 0.310 |
Why?
|
| Norethindrone | 1 | 2009 | 13 | 0.310 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 1463 | 0.300 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2009 | 106 | 0.290 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2019 | 170 | 0.270 |
Why?
|
| Vacuum Curettage | 1 | 2007 | 5 | 0.270 |
Why?
|
| Mice | 12 | 2020 | 12537 | 0.270 |
Why?
|
| Models, Biological | 1 | 2015 | 1809 | 0.270 |
Why?
|
| Tramadol | 1 | 2007 | 14 | 0.270 |
Why?
|
| Ibuprofen | 1 | 2007 | 33 | 0.270 |
Why?
|
| Policy Making | 2 | 2017 | 63 | 0.260 |
Why?
|
| Neoplasm Staging | 3 | 2025 | 2042 | 0.260 |
Why?
|
| Disease Models, Animal | 3 | 2011 | 2534 | 0.250 |
Why?
|
| Nutrition Surveys | 2 | 2024 | 125 | 0.250 |
Why?
|
| Neoplasms | 4 | 2021 | 3242 | 0.250 |
Why?
|
| Health Policy | 2 | 2017 | 208 | 0.230 |
Why?
|
| Signal Transduction | 2 | 2015 | 3581 | 0.220 |
Why?
|
| Pain | 1 | 2007 | 426 | 0.220 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2025 | 92 | 0.210 |
Why?
|
| Triticum | 1 | 2024 | 35 | 0.210 |
Why?
|
| Neoplasm Invasiveness | 5 | 2014 | 579 | 0.210 |
Why?
|
| Diet | 2 | 2024 | 460 | 0.210 |
Why?
|
| Mice, Nude | 4 | 2020 | 830 | 0.200 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 1230 | 0.200 |
Why?
|
| Animals | 13 | 2020 | 28889 | 0.200 |
Why?
|
| Cell Proliferation | 5 | 2020 | 1753 | 0.190 |
Why?
|
| Aged | 8 | 2025 | 20848 | 0.190 |
Why?
|
| Neoplasm Metastasis | 4 | 2020 | 1079 | 0.190 |
Why?
|
| Drinking Water | 1 | 2023 | 70 | 0.190 |
Why?
|
| Fatty Acid-Binding Proteins | 2 | 2020 | 25 | 0.180 |
Why?
|
| Neoadjuvant Therapy | 1 | 2025 | 449 | 0.170 |
Why?
|
| Faculty, Medical | 1 | 2023 | 207 | 0.170 |
Why?
|
| Pregnancy | 4 | 2021 | 3237 | 0.170 |
Why?
|
| Double-Blind Method | 1 | 2025 | 1791 | 0.170 |
Why?
|
| Blotting, Western | 2 | 2014 | 796 | 0.170 |
Why?
|
| Disease-Free Survival | 2 | 2014 | 1194 | 0.160 |
Why?
|
| Calcium | 2 | 2023 | 1205 | 0.150 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2021 | 176 | 0.150 |
Why?
|
| Tumor Burden | 3 | 2020 | 322 | 0.150 |
Why?
|
| Telephone | 1 | 2019 | 36 | 0.150 |
Why?
|
| Retinal Dehydrogenase | 1 | 2019 | 7 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 644 | 0.150 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 528 | 0.150 |
Why?
|
| Stromal Cells | 1 | 2019 | 152 | 0.150 |
Why?
|
| Genetic Counseling | 1 | 2019 | 102 | 0.150 |
Why?
|
| Middle Aged | 8 | 2025 | 28208 | 0.140 |
Why?
|
| Sphingosine | 1 | 2019 | 74 | 0.140 |
Why?
|
| Lysophospholipids | 1 | 2019 | 67 | 0.140 |
Why?
|
| Adult | 8 | 2025 | 28578 | 0.140 |
Why?
|
| Sodium, Dietary | 1 | 2017 | 9 | 0.130 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2017 | 10 | 0.130 |
Why?
|
| Carcinogenesis | 1 | 2019 | 235 | 0.130 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2019 | 182 | 0.130 |
Why?
|
| Neoplastic Stem Cells | 1 | 2019 | 173 | 0.130 |
Why?
|
| Apoptosis | 3 | 2014 | 1756 | 0.130 |
Why?
|
| Cell Survival | 2 | 2020 | 1029 | 0.130 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2017 | 35 | 0.130 |
Why?
|
| Internet | 1 | 2019 | 340 | 0.130 |
Why?
|
| Fallopian Tubes | 1 | 2017 | 49 | 0.130 |
Why?
|
| Chemoprevention | 1 | 2017 | 93 | 0.130 |
Why?
|
| Omentum | 2 | 2020 | 68 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 307 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 3 | 2019 | 1046 | 0.120 |
Why?
|
| Carbon | 1 | 2016 | 97 | 0.120 |
Why?
|
| Enzyme Inhibitors | 1 | 2019 | 655 | 0.120 |
Why?
|
| Phenformin | 1 | 2015 | 6 | 0.120 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2015 | 14 | 0.120 |
Why?
|
| Glucose | 2 | 2016 | 701 | 0.120 |
Why?
|
| Aspirin | 1 | 2017 | 169 | 0.120 |
Why?
|
| Retrospective Studies | 3 | 2016 | 10273 | 0.120 |
Why?
|
| Ascites | 1 | 2015 | 57 | 0.110 |
Why?
|
| Genetic Testing | 1 | 2019 | 565 | 0.110 |
Why?
|
| Lactic Acid | 1 | 2015 | 108 | 0.110 |
Why?
|
| Cell Movement | 1 | 2019 | 816 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 491 | 0.110 |
Why?
|
| Survival Rate | 2 | 2016 | 1971 | 0.110 |
Why?
|
| Lovastatin | 1 | 2014 | 28 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 152 | 0.110 |
Why?
|
| MAP Kinase Signaling System | 1 | 2015 | 206 | 0.110 |
Why?
|
| Argentina | 2 | 2024 | 15 | 0.110 |
Why?
|
| Fibronectins | 1 | 2014 | 100 | 0.100 |
Why?
|
| Drug Synergism | 1 | 2014 | 317 | 0.100 |
Why?
|
| Likelihood Functions | 1 | 2014 | 257 | 0.100 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 484 | 0.100 |
Why?
|
| Mass Screening | 1 | 2018 | 710 | 0.100 |
Why?
|
| Child | 5 | 2024 | 7618 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 569 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 897 | 0.090 |
Why?
|
| Mitochondria | 1 | 2016 | 621 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2017 | 9167 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 3491 | 0.090 |
Why?
|
| Oxidative Stress | 1 | 2015 | 473 | 0.090 |
Why?
|
| Estrogen Antagonists | 1 | 2011 | 48 | 0.090 |
Why?
|
| Cell Growth Processes | 1 | 2011 | 83 | 0.090 |
Why?
|
| Anoikis | 1 | 2011 | 7 | 0.090 |
Why?
|
| Coculture Techniques | 3 | 2020 | 172 | 0.090 |
Why?
|
| Drug Interactions | 1 | 2011 | 245 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2019 | 2473 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2011 | 81 | 0.080 |
Why?
|
| Anilides | 1 | 2011 | 46 | 0.080 |
Why?
|
| Prognosis | 2 | 2016 | 3990 | 0.080 |
Why?
|
| Mice, Transgenic | 2 | 2011 | 1645 | 0.080 |
Why?
|
| Infant | 3 | 2023 | 3360 | 0.080 |
Why?
|
| Quinolines | 1 | 2011 | 89 | 0.080 |
Why?
|
| Child, Preschool | 3 | 2024 | 3970 | 0.080 |
Why?
|
| Adipose Tissue | 1 | 2013 | 271 | 0.080 |
Why?
|
| Ovary | 1 | 2011 | 267 | 0.080 |
Why?
|
| fas Receptor | 1 | 2010 | 76 | 0.080 |
Why?
|
| Peritoneal Neoplasms | 1 | 2011 | 187 | 0.080 |
Why?
|
| Gonadotropins | 1 | 2009 | 34 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2011 | 200 | 0.080 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2009 | 48 | 0.080 |
Why?
|
| Integrases | 1 | 2009 | 67 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 297 | 0.070 |
Why?
|
| Male | 7 | 2024 | 45686 | 0.070 |
Why?
|
| Mutation | 2 | 2018 | 4374 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 3904 | 0.070 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2009 | 149 | 0.070 |
Why?
|
| Estrogens | 1 | 2009 | 202 | 0.070 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2009 | 180 | 0.070 |
Why?
|
| Abortion, Therapeutic | 1 | 2007 | 11 | 0.070 |
Why?
|
| Cohort Studies | 1 | 2014 | 3106 | 0.070 |
Why?
|
| Chicago | 1 | 2012 | 1505 | 0.060 |
Why?
|
| Analgesics | 1 | 2007 | 132 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 3639 | 0.060 |
Why?
|
| Young Adult | 3 | 2024 | 7026 | 0.060 |
Why?
|
| Biomarkers, Tumor | 1 | 2014 | 1670 | 0.060 |
Why?
|
| Adolescent | 3 | 2024 | 9873 | 0.060 |
Why?
|
| Lipid Metabolism | 2 | 2020 | 220 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 3155 | 0.050 |
Why?
|
| Mice, Knockout | 1 | 2009 | 2161 | 0.050 |
Why?
|
| Food Handling | 1 | 2023 | 7 | 0.050 |
Why?
|
| Fast Foods | 1 | 2023 | 5 | 0.050 |
Why?
|
| Immunity, Humoral | 1 | 2024 | 74 | 0.050 |
Why?
|
| Drinking | 1 | 2023 | 35 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2024 | 246 | 0.050 |
Why?
|
| Immunity, Cellular | 1 | 2024 | 189 | 0.050 |
Why?
|
| Water Supply | 1 | 2023 | 66 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2024 | 163 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2024 | 348 | 0.040 |
Why?
|
| Recommended Dietary Allowances | 1 | 2021 | 3 | 0.040 |
Why?
|
| Diet Records | 1 | 2021 | 20 | 0.040 |
Why?
|
| Diethylstilbestrol | 1 | 2021 | 119 | 0.040 |
Why?
|
| Hip Fractures | 1 | 2021 | 51 | 0.040 |
Why?
|
| Developing Countries | 1 | 2021 | 91 | 0.040 |
Why?
|
| Succinate-CoA Ligases | 1 | 2019 | 2 | 0.040 |
Why?
|
| Prolyl Hydroxylases | 1 | 2019 | 4 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2019 | 4664 | 0.040 |
Why?
|
| Protein Array Analysis | 1 | 2020 | 52 | 0.040 |
Why?
|
| Eating | 1 | 2021 | 165 | 0.040 |
Why?
|
| Biphenyl Compounds | 1 | 2020 | 62 | 0.040 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2020 | 28 | 0.040 |
Why?
|
| Risk | 1 | 2021 | 665 | 0.040 |
Why?
|
| Heterografts | 1 | 2020 | 117 | 0.040 |
Why?
|
| Metabolomics | 1 | 2020 | 98 | 0.040 |
Why?
|
| AC133 Antigen | 1 | 2019 | 10 | 0.040 |
Why?
|
| Bone Density | 1 | 2021 | 239 | 0.040 |
Why?
|
| Poverty | 1 | 2021 | 196 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 256 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 205 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2019 | 64 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2020 | 161 | 0.040 |
Why?
|
| 5-Methylcytosine | 1 | 2020 | 122 | 0.040 |
Why?
|
| Carboplatin | 1 | 2020 | 328 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 1878 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2020 | 526 | 0.040 |
Why?
|
| Proteomics | 1 | 2020 | 268 | 0.030 |
Why?
|
| Diet Surveys | 1 | 2017 | 21 | 0.030 |
Why?
|
| Education | 1 | 2017 | 60 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2020 | 740 | 0.030 |
Why?
|
| Incidence | 1 | 2021 | 1714 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 547 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2021 | 1010 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2021 | 1158 | 0.030 |
Why?
|
| Metabolome | 1 | 2016 | 63 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 2016 | 368 | 0.030 |
Why?
|
| Mammography | 1 | 2018 | 475 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2020 | 703 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 640 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1208 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2021 | 2611 | 0.030 |
Why?
|
| Integrins | 1 | 2014 | 79 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2014 | 89 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 404 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2014 | 430 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2014 | 255 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 562 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1965 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2011 | 411 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2010 | 22 | 0.020 |
Why?
|
| Fas Ligand Protein | 1 | 2010 | 50 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 264 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2011 | 686 | 0.020 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2010 | 59 | 0.020 |
Why?
|
| Hepatocytes | 1 | 2010 | 132 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2011 | 516 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 1559 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 611 | 0.020 |
Why?
|
| United States | 1 | 2019 | 7764 | 0.020 |
Why?
|
| Obesity | 1 | 2013 | 1030 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2010 | 790 | 0.010 |
Why?
|